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In order to investigate the generation and selection of hepatitis B virus mutants and the influence of interferon on their
evolution, a longitudinal study including 22 patients was performed. The complete preS1/S2 open reading frame was
analyzed by direct sequencing from serum samples obtained before and after seroconversion to anti-HBe in 11 children
without a-interferon treatment. Furthermore, in 11 cases with therapy additional samples obtained during interferon therapy
were investigated. The comparison of each patient’s preS sequences analyzed before and during therapy did not show any
nucleotide change, while in both groups numerous silent and missense mutations were found immediately after serocon-
version. Surprisingly, in 7 cases the hepatitis B virus changed genotype from A to D (subtype adw to ayw) after serocon-
version. Additional rearrangements were observed in 4 patients. In 3 cases the selection of preS2 start codon mutants was
detected after seroconversion and in 1 individual a 183-nucleotide deletion was found during and after HBeAg positivity. In
conclusion, the emergence of preS rearrangements and numerous base exchanges provide evidence for a strong selection
process focused against the preS region. Moreover, the appearance of genotype changes after anti-HBe seroconversion
reveales a thus far unrecognized event during the natural course of HBV infection in childhood. © 1998 Academic Press
INTRODUCTION
The hepatitis B (HBV) virus is a small, circular DNA
virus with four open reading frames. It causes a variety of
acute or chronic liver diseases in humans. Its envelope
consists of three distinct surface proteins, the so-called
large, middle, and small protein. These polypeptides are
encoded by the same open reading frame, including
three start codons and a common stop codon. The small
or major peptide (HBsAg) is 226 amino acids in length
and the middle and large proteins are assembled by
amino-terminal extension of 55 amino acids (aa) of the
preS2 region and of 108 to 119 amino acids (depending
on the strain) of the preS1 protein, respectively (Galibert
et al., 1979; Pasek et al., 1979; Valenzuela et al., 1979).
The preS proteins play an essential role in the inter-
action of the immune defense to viral immune recogni-
tion sites since they contain both B- and T-cell epitopes.
They were shown to provide protective immunity in chim-
panzee and mice (Gerlich et al., 1990; Neurath and
Thanavala, 1990; Milich et al., 1990). The preS1 protein
contains the hepatocyte-binding site (aa 21–47) and is
known to be essential for virion assembly and for the
transport of virions out of the hepatocyte (Ganem, 1991).
The role of the preS2 protein is less defined. It was
demonstrated to be dispensable for virion assembly,
infectivity, and secretion (Fernholz et al., 1991), but the
findings are discussed controversially (Ueda et al., 1991).
The genetic variability of the HBV genome, reflected in
various genotypes and subtypes, is well established.
While the HBV subtyping is based on specific amino acid
residues at positions 120, 126, and 160 within HBsAg, the
HBV genotypes differ by more than 8% in the protein
sequence of full-length genomic comparison (Peterson
et al., 1984; Okamoto et al., 1988; Ohnuma et al., 1993;
Norder et al., 1992). So far six different genotypes of the
HBV designated A–F have been isolated (Okamoto et al.,
1988; Norder et al., 1992). Especially within the hyper-
variable preS region, the genotypes differ in numerous
amino acids and some of them even in length. As in
many other viruses, there is strong evidence that the
principal T- and B-cell response is subtype- and geno-
type-specific (Cupps et al., 1993; Yamauchi et al., 1993).
Therefore it seems likely that alterations of the immune
epitopes could result in a decreased efficacy of the hosts
T- and B-cell response.
Recently, a number of preS1/S2 rearrangements, in-
cluding deletions and initiation codon mutants, have
been identified in patients with chronic and fulminant
hepatitis (Fernholz et al., 1991; Santantonio et al., 1992;
Uy et al., 1992; Melegari et al., 1994; Pollicino et al., 1995,
1997). The emergence or selection of these variants after
seroconversion to anti-HBe or during interferon therapy
argues for their importance to viral persistence and the
clinical outcome of the disease. However, since in most
of these studies the patients’ HBV molecules were ana-
lyzed only in one stage of the disease, the process of
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sequential changes and the time and reason for their
generation has not been well defined. Thus, the compar-
ison of HBV genomes derived from HBeAg- and anti-
HBe-positive phases of the same carrier may lead to a
better understanding of genetic heterogeneity and their
biological significance.
To date there is no information about sequential
changes in the preS region of the HBV genome or the
incidence of deletions before and after anti-HBe sero-
conversion in patients who were infected in childhood.
For this reason, we investigated the complete preS1/S2
region from sera of chronic HBV-infected children by
direct sequencing of amplified HBV DNA. Furthermore,
the effect of interferon treatment on the selection of
mutants was evaluated by comparing the sequential
changes of 11 treated with 11 untreated patients.
RESULTS
Comparison of the preS1/S2 ORF to the reference
sequences
Figure 1 illustrates all missense mutations, deletions,
and preS2 start codon mutations in comparison to the
reference sequences. The patients infected with geno-
type A showed the highest homology to the reference
sequence isolated by Valenzuela et al. (1979), while sub-
jects carrying HBV of genotype D were most similar to
the reference of Galibert et al. (1979). In one patient a
183-bp deletion and in three children preS2 start codon
mutations were detected. Moreover, numerous amino
acid changes were found in all subjects. There were
several regions with a higher frequency of mutations. In
children with genotype D a small region of seven amino
acids (aa 35–41) at the C terminal of preS2 displayed
many changes in all chronic carriers. In genotype A
isolates many missense mutations could be identified
especially in the middle of preS1 and at the very C
terminal of the preS2 ORF. Within the hepatocyte binding
site (aa 21–47) the number of missense mutations was
low. No relation was found between the number or the
position of missense mutations and histological inflam-
matory activity.
Sequential changes after seroconversion
The sequential changes of each case after serocon-
version to anti-HBe are summarized in Fig. 2. The most
striking finding was that 7 patients (P, Q, R, S, T, U, and
V) changed HBV genotype after anti-HBe seroconver-
sion. Moreover, all 7 patients belonged to the group of
11 children who seroconverted spontaneously without
having received a-interferon (IFN) treatment. No geno-
type replacement was observed in patients with inter-
feron therapy. Patients F, G, and I were already in-
fected with genotype D strains in the presence of
HBeAg. The 7 subjects changed from subtype adw of
genotype A to subtype ayw of genotype D. As demon-
strated in Fig. 4 all patients showed a mixed popula-
tion of genotypes A and D, which can be detected as
a double band differing in 33 nucleotides in the aga-
rose gel due to the lack of 11 amino acids at the amino
terminal of the preS1 ORF in most HBV genomes of
genotype D. Interestingly, genotype D always predom-
inated significantly over genotype A. Sequencing of
the additional six serum samples of subjects S, T, and
U confirmed that the genotype replacement always
correlated with the emergence of antibodies against
the e protein, as in none of these patients genotype
changes were detected in the presence of HBeAg,
while the mixed HBV genotype population persisted
after seroconversion (data not shown).
Since the existence of HBV mixed particles containing
genes related to different HBV genotypes has been re-
ported, the precore/core gene from three patients with
genotype replacements (patients S, T, and U) was ana-
lyzed. From each child one HBeAg-positive serum sam-
ple and one anti-HBe-positive sample was amplified and
sequenced.
Both the precore and the core sequences showed
genotype A-related nucleotides in the presence of
HBeAg. After anti-HBe seroconversion the precore gen-
otype-related nucleotides at positions 1850 and 1858
changed from 1850A/1858C (genotype A) to 1850T/1858T
(genotype D).
The HBV core gene of genotype D differs in a 6-nu-
cleotide deletion to genotype A. This deletion could be
identified in all three patients only after anti-HBe sero-
conversion. Therefore it seems likely that the isolated
viruses after seroconversion are full-length HBV ge-
nomes of genotype D.
The high number of aa substitutions in patients who
changed the genotype, illustrated in Fig. 2, is mostly due
to genotype-related differences in the amino acid se-
quence. Most of the serum samples of these patients are
obtained between 12 and 48 months after seroconver-
sion. However, in cases S and T a heterogeneous viral
population of genotypes A and D was already observed
1 month after the appearance of anti-HBe.
Numerous silent and missense mutations were
identified in 19 cases. These mutations frequently re-
sulted in alteration of immunological target sites since
many T- and B-cell epitopes have been described so
far within the preS region (illustrated at the bottom of
Fig. 2), (Neurath et al., 1989; Milich, 1988; Ferrari et al.,
1992).
Only patients B, C, F, and L, from whom the HBV DNA
was analyzed immediately after seroconversion, pre-
sented no change within the preS1/S2 region after the
emergence of antibodies against the HBe antigen.
Additional preS rearrangements
In one child (patient F) in the amplified sera before
and after anti-HBe seroconversion the agarose gel
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revealed, besides the expected band, a second
smaller amplification product. The amplified HBV DNA
was then subcloned. Six of 18 clones were consistent
with a deletion and 12 showed wildtype length. The
sequence analysis of the smaller fragment revealed a
183-nt in-frame deletion at the C-terminal of preS1 in
all 6 clones. Amplification of additional samples re-
vealed that the preS1 deletion mutant became visible
FIG. 1. PreS1/S2 sequences from 22 patients A–V in comparison to the reference sequences indicated in bold letters at the top. The numbers after
the patient’s letters denote the serological status in which the serum sample was obtained: (1) before anti-HBe seroconversion; (3) after anti-HBe
seroconversion. Only amino acids different from the reference sequences are indicated; () deletion; shaded amino acids indicate start codon
mutants; dots represent genotype-related deletions.
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even before a-interferon therapy was started (data not
shown).
In three other children important changes were regis-
tered. In patients K and O the preS2 start codon mutated
from ATG to ACG and in patient N to ATA, resulting in
nonexpression of the preS2 protein.
The sensitivity of direct sequencing to detect minor
populations, which is approximately 10%, allowed us
to identify the coexistence of HBV strains with wildtype
and mutated preS2 start codons. Quantification of the
heterogeneous viral population according to Leitner et
al., (1993) revealed a wildtype:variant ratio of roughly
1:3 in the presence of HBeAg. After anti-HBe serocon-
version the preS2-defective particles predominated
clearly, in a ratio of 4:1.
Frequency of base exchanges
Figure 2 presents the number of missense mutations
after anti-HBe seroconversion in all 22 children. No clus-
ter or hot spot of mutations could be registered.
The complete preS ORF was investigated 1 to 48
months after seroconversion. In Fig. 3 the number of
nucleotide substitutions after seroconversion is shown in
relation to the time after seroconversion. The rapid emer-
gence of nucleotide changes immediately after serocon-
version is reflected in patients I, J, and G, where within
the first 2 months one to three exchanges could be
identified. This is not the case in four other subjects (B,
C, F, and L), in which no sequential differences were
observed. Altogether it is remarkable that the number of
FIG. 2. Comparison of amino acid changes within each patient’s preS1/S2 ORF before and after anti-HBe seroconversion of 22 patients, A–V. The
sequences different from the sequence before seroconversion are indicated: (_) amino acid change; (black box) deletion; (shaded boxes) genotype-
related deletion of 33 nucleotides in genotype D; ( p ) start codon mutation.
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nucleotide substitutions is increasing with the time after
seroconversion. For example, among patients B, C, F, L,
and I, who were investigated 1 month after seroconver-
sion, only one case showed one nucleotide exchange.
This is quite in contrast to patients analyzed more than 1
year after emergence of anti-HBe, where 3 to 25 base
exchanges could be detected (patients O, A, D, E, and K;
see Fig.3). Nucleotide exchanges in patients L–V are not
shown, since most of the changes after seroconversion
are due to the genotype change.
Mutations in patients with and without a-interferon
As shown in Fig. 1 no significant difference in the
number or position of mutations was observed between
patients with a-interferon therapy in comparison to pa-
tients without treatment. PreS2 start codon mutants were
identified in two children without interferon treatment
and in one case with interferon-induced seroconversion.
The preS1 deletion emerged in a patient with interferon
therapy but the selection process had already started
before the initial dose of a-interferon was given. How-
ever, it was remarkable that none of the seven patients
with HBV genotype changes did receive a-interferon.
DISCUSSION
In the present study, we have analyzed the HBV preS
region in the high replicative HBeAg-positive phase and
the low replicative anti-HBe-positive phase. Anti-HBe se-
roconversion occurred either spontaneously or after
a-interferon treatment. Numerous base exchanges and
rearrangements were identified. However, the most strik-
ing finding was the frequent change of genotype A to D
(subtype adw to ayw) in children with spontaneous con-
version to anti-HBe. This was in contrast to individuals
with interferon-induced seroconversion, where in none
of them a genotype replacement was observed. This
might have happened incidentally since we had also
identified genotype changes in some patients with inter-
feron therapy (Bahn et al., 1997). Although in most of the
children the period between seroconversion and time of
sequencing was more than 16 months, the emergence of
genotype D strains 1 month after anti-HBe seroconver-
sion in two patients (S and T) argues for a rapid selection
process triggered by the increased immunological activ-
ity resulting in antibodies against the e antigen. Se-
quencing of only one sample during HBeAg positivity will
fail to detect genotype changes during this serological
state. Therefore, six additional serum samples from pa-
tients S, T, and U were investigated. The results con-
firmed that only after anti-HBe seroconversion can a
genotype change be observed. Moreover, the coexist-
ence of genotypes A and D persisted in all patients,
similar to what is presented in Fig. 4.
We tried to find the meaning of the appearance of
other genotypes. The transition from an relative immune
tolerant state to activation of the immune system with
generation of antibodies against HBeAg results in a
strong selection pressure on the viral genomes. Since
the preS region is highly immunogenic at the T- and
B-cell level, mutations causing changes of immune tar-
get sites such as T- and B-cell epitopes could lead to
escape of the virus from immune clearance. This effect
could be established directly or indirectly through re-
duced binding affinity of antibodies or by MHC class
FIG. 3. Number of nucleotide exchanges from patients A–O in relation to the time after anti-HBe seroconversion. Indicated are three periods: (black
columns) 0–2 months; (shaded columns) 4–8 months; (checkered columns) 16–36 months.
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I-mediated presentation of modified oligopeptides on the
cell surface of hepatocytes, respectively. It is conceiv-
able that these effects are reached by changing the
genotype because they differ in numerous amino acids
in the preS ORF. This theory is supported by the obser-
vation that the T- and B-cell response is mostly subtype-
specific (Milich et al., 1990).
In our understanding the prerequisite for a genotype
change would be a simultaneous infection with different
genotypes. Since the evolution of a new genotype within
such a short period of time seems to be very unlikely,
only patients harboring at least two different HBV geno-
types within their heterogeneous viral pool at the time of
infection would have the chance to select another one
under certain immunological conditions. Moreover, our
results suggest that these selected genotypes are not
only present in the preS region. The precore and core
regions showed genotype A-related sequences in the
presence of HBeAg, whereas after anti-HBe seroconver-
sion in all subjects genotype D-specific nucleotide ex-
changes and the genotype D-related 6-nucleotide dele-
tion in the core gene was found. For this reason it
appears that HBV particles of full-length genotype D
were selected after seroconversion.
To our knowledge this is the first study that provides
proof of genotype changes during the natural course of
HBV infection. However, two further studies support our
findings. Gu¨nther et al., (1992) found after anti-HBe se-
roconversion point mutations within the preC region in
patients who were mostly specific for HBV strains of
genotype D. In the same patients they were absent in the
HBeAg-positive phase. In addition, Li et al. (1993) de-
tected in most subjects genotype A during HBeAg posi-
tivity, whereas in another population of patients who had
already seroconverted to anti-HBe mostly viral strains of
genotype D were found. Taken together with our own
results these data suggest that HBV genotype changes
in adulthood are also a frequent event after anti-HBe
seroconversion.
Furthermore, numerous missense and silent muta-
tions in the preS1/S2 region were identified after anti-
HBe seroconversion. One important cause of the gener-
ation of mutations in HBV is the lack of a proofreading
activity of the DNA polymerase protein (Coffin, 1986;
Dougherty and Temin, 1988). Okamoto et al. (1987) re-
ported the emergence of only 11 nucleotide substitutions
in a chronic HBV carrier after 54 years of infection. Thus,
the evolutionary rate of genetic changes in the HBV
genome was estimated to be approximately 4.6 3 1025
per site per year (Okamoto et al., 1987; Orito et al., 1989).
However, this natural mutation rate is much smaller than
the rate of mutations found in our patients after serocon-
version, probably due to the above-mentioned mecha-
nism of enhanced immunological pressure on the HBV
genomes during the process of anti-HBe seroconver-
sion. A T- or B-cell-dependent viral selection process has
not yet been proven. Nevertheless, the high mutation
rate after conversion and the finding that many of the
changes occurred in immune epitopes so far recognized
supports the idea of the biological significance of emerg-
ing HBV variants, particularly within the core, preS, and
surface ORFs, which have all been described as con-
taining immune epitopes.
Recently, preS2 start codon mutants have been de-
scribed in chronic HBV carriers (Santantonio et al., 1992;
Gerken et al., 1991; Fernholz et al., 1991; Pollicino et al.,
1997). Due to a point mutation or to deletions these
mutant genomes are unable to express the preS2 pro-
tein. All of the preS2-defective genomes were found in
the presence of anti-HBe. In our investigation, three
patients had start codon mutations. Since there is in-
creasing evidence that the preS2 proteins are not essen-
tial for virion assembly, infectivity, and secretion (Fern-
holz et al., 1991; Pollicino et al., 1997) the virus is able to
dispense with it. It was demonstrated that a major B-cell
epitope is located at the amino terminal of this region
(Neurath and Thanavala, 1990). Therefore, it is conceiv-
able that under the condition of increased immune pres-
sure of the anti-HBe seroconversion process the advan-
tage of getting rid of preS2 proteins could exceed the
benefits of producing it. Interestingly, in one patient a
mutant/wildtype coexistence was detected both in the
FIG. 4. Genotyping by size polymorphism of the preS region. Shown are the seven patients (P–V) with genotype changes. For each subject two
panels with PCR products before (1) and after (3) anti-HBe seroconversion are demonstrated. The expected amplification fragments were 588 nt for
genotype A and 555 nt for genotype D.
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HBeAg-positive phase and after seroconversion. How-
ever, this theory is underlined by the fact that the ratio of
the mixed population shifted significantly to a wildtype
presence of only around 20% after anti-HBe seroconver-
sion, while during the HBeAg-positive phase the wildtype
predominated clearly, with approximately 75% over mu-
tant preS2 start codon molecules.
Santantonio et al. (1992) suggested that the generation
of preS2-defective mutants was triggered by IFN treat-
ment. In view of our results this seems unlikely. Two of
three children with preS2 start codon mutants were not
treated with IFN.
In one of our patients a hepatitis B virus lacking 183
bases in the preS1 region emerged during the course of
infection. The fact that this mutation has been found in a
number of chronically HBV-infected patients (Gerken et
al., 1991; Seminago et al., 1993; Takayanagi et al., 1993;
Nakajima et al., 1994; Melegari et al., 1994) supports the
idea that it does not occur randomly but is due to donor
and acceptor splice sites. One important consequence of
the deletion is the removing of the promoter of the small
envelope protein. Therefore, the preS1-deleted genomes
are no longer able to produce HBsAg (Melegari et al.,
1997). In addition, Melegari et al. (1997) found that the
183-nt deletion HBV genomes were retained with the
cytoplasm. Only after coexpression with the small enve-
lope protein could the mutant genomes be secreted into
the cell supernatant. This finding explains why the de-
leted variant was always accompanied by HBV genomes
of wildtype length. In contrast to all other cases reported
with the same mutation, in our patient the deletion was
detected even before IFN treatment was started and
thus, the selection of this mutant must have other causes
than the use of IFN.
In conclusion, our data indicate that the appearance of
antibodies against the e antigen results not only in in-
creased immunological pressure against the e protein
and consequently the preCore region. The generation of
preS mutations and rearrangements after anti-HBe sero-
conversion suggests a selection process that is also
concentrated against the preS ORF.
Especially surprising was the finding of HBV genotype
replacements. This may induce a change in the antigenic
masc, which the virus presents to the immune system, as
HBV genotypes differ in numerous amino acids and
therefore would lead to altered T- and B-cell target sites.
The consequences and mechanisms of these selections
have to be clarified in further studies.
MATERIALS AND METHODS
Patients
Sera of 22 children with chronic active hepatitis (CAH),
chronic persistent hepatitis (CPH), or minimal hepatitis
(MH), according to the criteria of de Groote et al. (1968),
were collected from different stages of the disease with
a median followup of 40 months (clinical and laboratory
data are shown in Table 1). Patients A–K were treated
with a-IFN and three different serum samples before
seroconversion to anti-HBe, during interferon therapy,
and after seroconversion were obtained from each sub-
ject. In the second group patients L–V seroconverted
spontaneously to anti-HBe. Two serum samples were
taken before and after seroconversion to anti-HBe. All
samples were HBsAg positive.
The sera of the 7 patients with genotype replacements
have been collected in four different hospitals in Ger-
many. None of these infants was related to any of the
other patients included in this study. Furthermore, to our
knowledge none of these 7 children received blood at
any time. Therefore, an epidemiological link among them
seems unlikely. Most of them were infected perinatally
with HBV.
To further evaluate the process of genotype changes
during chronic hepatitis, 6 additional serum samples
obtained both during the presence of the e Ag and after
the appearance of anti-HBe from 3 patients with geno-
type changes (patients S, T, and U) were sequenced.
Serological markers
HBsAg, HBeAg, anti-HBe, anti-HBs, and anti-HBc were
assayed using commercial radioimmunoassays (Abbott
Laboratories, North Chicago, IL). All patients were neg-
ative for antibodies to hepatitis C virus, hepatitis D virus,
and human immunodeficiency virus. HBV DNA was de-
termined quantitatively by a liquid hybridization assay
(Hybride Capture Systems, Digene Diagnostics, Belts-
ville, MD).
PCR amplification, subcloning, and sequencing
An aliquot of 200 ml of each patient’s serum was
obtained to isolate viral DNA with the QIAamp Blood Kit
(Qiagen, Chatsworth, CA). The DNA was eluted with 50
ml distilled water according to the manufacturer’s recom-
mendations. The preS1/S2 open reading frame was am-
plified by PCR in 50 ml of buffer containing 300 mM
Tris–HCL (pH 8.5), 75 mM (NH4)2SO4, 1.0 mM MgCl2, 400
mM deoxynucleoside triphosphates (dNTPs), 1 U of Taq
polymerase (Boehringer Mannheim, Germany), and 30
pmol each of primers P1 and P2 (P1, 59-GGG TCA CCT
TAT TCT TGT-39, nucleotides 2816–2833; P2, 59-GTC CTA
GGA ATC CTG ATG-39, nucleotides 173–189). The PCR
was performed for 35 cycles at 94°C for 1 min, 58°C for
30 s, and 72°C for 1 min in a thermal cycler (Perkin–
Elmer Cetus, Norwalk, CT). The PCR products were vi-
sualized after electrophoresis in a 2% agarose gel and
with ethidium bromide staining. In order to minimize
artificial mutagenesis for samples not detectable after
the first amplification, a second PCR was performed with
30 cycles; 1 U Taq DNA–Pwo DNA polymerase (Expand
High Fidelity assay; Boehringer Mannheim) was used. In
contrast to the Taq enzyme, the Pwo polymerase has a
proofreading activity.
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TABLE 1
Clinical and Laboratory Data of 22 Patients, A–V
Patient Sex Age
Serological status
HBV DNA
(pg/ml)
ALT
(IU/ml) HistologyHBeAg anti-HBe HBsAg
Patients with interferon treatment
1 12.4 1 2 1 313 475
A 2 m 12.7 1 2 1 49 200 CPH
3 13.7 2 1 1 2 54
1 4.4 1 2 1 26 75
B 2 f 4.5 1 2 1 459 na CAH
3 6.5 2 1 1 2 24
1 2.2 1 2 1 58 90
C 2 m 2.5 1 2 1 15 33 CAH
3 3.2 2 1 1 2 25
1 12.3 1 2 1 159 52
D 2 f 12.8 1 2 1 8 28 CAH
3 16.2 2 1 1 2 26
1 5.9 1 2 1 107 85
E 2 m 6.1 1 2 1 72 185 CAH
3 8.0 2 1 1 2 18
1 12.1 1 2 1 133 41
F 2 m 12.7 1 2 1 72 19 CPH
3 13.2 2 1 1 2 18
1 3.2 1 2 1 70 120
G 2 m 4.1 1 2 1 12 306 MH
3 4.7 2 1 1 2 27
1 4.6 1 2 1 160 24
H 2 m 5.0 1 2 1 13 31 MH
3 8.0 2 1 1 2 11
1 1.5 1 2 1 170 83
I 2 f 1.7 1 2 1 139 55 CAH
3 3.2 2 1 1 2 31
1 7.0 1 2 1 77 80
J 2 m 8.6 1 2 1 92 na CPH
3 9.3 2 1 1 2 25
1 4.7 1 2 1 63 29
K 2 m 5.0 1 2 1 128 71 CAH
3 8.5 2 1 1 7 42
Patients without interferon treatment
L 1 12.2 1 2 1 175 76 CPH
3 m 16.5 2 1 1 2 12
M 1 7.0 1 2 1 87 19 CAH
3 f 11.0 2 1 1 2 13
N 1 14.2 1 2 1 54 16 CAH
3 m 21.7 2 1 1 2 13
O 1 4.3 1 2 1 39 19 CAH
3 m 14.7 2 1 1 2 12
P 1 10.2 1 2 1 41 65 CPH
3 m 17.9 2 1 1 2 13
Q 1 8.5 1 2 1 334 425 CAH
3 f 15.0 2 1 1 2 10
R 1 11.0 1 2 1 150 40 CAH
3 f 14.5 2 1 1 2 11
S 1 14.1 1 2 1 114 64 CPH
3 m 17.5 2 1 1 2 21
T 1 2.5 1 2 1 187 249 CAH
3 f 3.3 2 1 1 2 19
U 1 13.1 1 2 1 32 36 CAH
3 m 21.7 2 1 1 2 14
V 1 9.6 1 2 1 187 70 CAH
3 m 12.0 2 1 1 2 14
Note. Samples of patients (1) before seroconversion; (2) during interferon therapy; (3) after seroconversion; na, not available.
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To evaluate whether only the preS regions demon-
strate genotype D-related changes in patients with ge-
notype replacements, the precore/core gene was ampli-
fied and sequenced from patients S, T, and U as de-
scribed above with the following primers: precore region
(P3, 59-TGT CAA CGA CCG ACC TTG AG-39, nucleotides
1681–1700; P4, 59-CAA TGC TCA GGA GAC TCT AAG
GC-39, nucleotides 2043–2021); core region (P5, 59-TTT
TTC ACC TCT GCC TAA TCA-39, nucleotides 1821–1841;
P6, 59-TTG GGA TTG AAG TCC CAA TCT GG-39, nucle-
otides 2957–2935).
The amplified preS1/S2 ORF of patient F and of pa-
tients with genotype changes after anti-HBe seroconver-
sion were inserted by blunt-end ligation into a ECO
RV-digested Bluescript plasmid (Stratagene). The recom-
binant plasmids were introduced in Escherichia coli
DH5a (BRL) and cloned. One clone of wildtype and six
clones of deleted length were sequenced from patient F.
In patients with genotype changes only one clone of
genotype D length was sequenced, reflecting the major
population after anti-HBe seroconversion (see Fig. 4).
Plus and minus strands were sequenced with primers
P1 and P2 using a Dye Terminator Cycle Sequencing Kit
(ABI PRISM, Foster City, CA) in an automated sequencer,
Model 377 (ABI).
Analysis of sequences and genotyping
According to sequence alignments with previously
published HBV genomes (for genotypes A–F, Galibert et
al., 1979; Pasek et al., 1979; Valenzuela et al., 1979;
Bichko et al., 1985; Tong et al., 1990; Sastrosowignijo et
al., 1987; Okamoto et al., 1987; Fujiyama et al., 1983;
Vaudin et al., 1988), the HBV strains were classified to the
non-Asian genotypes A or D. In addition, sequence data
of each patient were compared with each other. Se-
quence alignments were performed using the Se-
quencher 3.0 software program.
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